Literature DB >> 2183470

High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants.

P K Chanda1, R J Natuk, B B Mason, B M Bhat, L Greenberg, S K Dheer, K L Molnar-Kimber, S Mizutani, M D Lubeck, A R Davis.   

Abstract

The effect of rev (art/trs) gene on the level of HIV-1 envelope (env) expression using recombinant adenovirus was investigated. Recombinant adenoviruses expressing either the envelope or the rev gene of the human immunodeficiency virus type 1 (HIV-1) were constructed by inserting the gene into an expression cassette. The expression cassette contained the adenovirus type 7 major late promoter, followed by leader 1 of the adenovirus tripartite leader and a portion of intron between leaders 1 and 2, leaders 2 and 3, and a hexon polyadenylation signal. The cassette was then inserted at the terminal region between the E4 and ITR regions of the adenovirus 7 genome with a concomitant E3 region deletion (80-87 m.u.). A549 cells infected with the recombinant virus containing the env gene produced the envelope glycoproteins gp160, gp120, and gp41. HIV-1 envelope gene expression was greatly enhanced (20- to 50-fold) in the cells that were simultaneously infected with the recombinant adenovirus containing the rev gene as measured by ELISA and Western blotting. Interestingly, this effect was observed despite the lack of the 5' down splice site for rev and seems to be post-transcriptional. Another recombinant adenovirus which contains both the rev and the env genes was constructed by inserting the rev gene in the deleted E3 region and the env gene in the terminal cassette. This double recombinant virus expressed high levels of env antigen in A549 cells similar to those attained upon co-infection with two separate recombinant viruses containing the rev or env gene. Furthermore, the rev gene nucleotide sequence could be altered without altering the amino acid sequence and its sequences truncated by 17 amino acids from the C-terminus had no effect of rev function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183470     DOI: 10.1016/0042-6822(90)90438-w

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Rev-dependent expression of human immunodeficiency virus type 1 gp160 in Drosophila melanogaster cells.

Authors:  M Ivey-Hoyle; M Rosenberg
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

2.  Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome.

Authors:  S Miyake; M Makimura; Y Kanegae; S Harada; Y Sato; K Takamori; C Tokuda; I Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

Review 3.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

4.  Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

Authors:  L Jean Patterson; Nina Malkevitch; Joel Pinczewski; David Venzon; Yuanmei Lou; Bo Peng; Cindy Munch; Melissa Leonard; Ersell Richardson; Kristine Aldrich; V S Kalyanaraman; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant.

Authors:  S M Cheng; S G Lee; M Ronchetti-Blume; K P Virk; S Mizutani; J W Eichberg; A Davis; P P Hung; V M Hirsch; R M Chanock
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

Authors:  R J Natuk; P K Chanda; M D Lubeck; A R Davis; J Wilhelm; R Hjorth; M S Wade; B M Bhat; S Mizutani; S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 7.  Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.

Authors:  Martí Farrera-Sal; Cristina Fillat; Ramon Alemany
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

8.  Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.

Authors:  Michael A Thomas; Rui Song; Thorsten Demberg; Diego A Vargas-Inchaustegui; David Venzon; Marjorie Robert-Guroff
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

9.  HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.

Authors:  Edward Yang; Matthew R Gardner; Amber S Zhou; Michael Farzan; Ann M Arvin; Stefan L Oliver
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.